Sarafloxacin
Based on 2 publication(s) in Google Scholar
Sarafloxacin (A-56620) is a fluoroquinolone Antibacterial agent. Sarafloxacin inhibits the growth of Staphylococcus aureus, Enterobacteriaceae, and both aminoglycoside-sensitive and aminoglycoside-resistant strains of Pseudomonas aeruginosa.
For research use only. We do not sell to patients.
- Purity : 98.43%
- CAS No.: 98105-99-8
- Formula: C20H17F2N3O3
- Molecular Weight:385.36
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sarafloxacin
More
Biological Activity
Description
IC50 & Target
|
Quinolone |
In Vitro
Sarafloxacin (18 h) inhibits the growth of intestinal E. coli strains (MIC50 = 0.63 μg/mL), B. fragilis strains (MIC50 = 8.2 μg/mL) and Bifidobacterium strains (MIC50 = 7.2 μg/mL) in an in vitro simulated intestinal model[1].
Sarafloxacin (0.5-1 mg/L; 20 h) exhibits activity against staphylococci, including multidrug-resistant *Staphylococcus aureus*[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 98105-99-8
-
Appearance Solid
-
Molecular Weight 385.36
-
Formula C20H17F2N3O3
-
Color White to off-white
-
SMILES
O=C(C1=CN(C2=CC=C(F)C=C2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
-
Synonyms
A-56620
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Biol Chem
Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice. [Abstract]2022 Feb;298(2):101554. PMID: 34973337 -
Microb Pathog
Antibiotic discovery against Piscirickettsia salmonis using a combined in silico and in vitro approach. [Abstract]2023 Jul:180:106122. PMID: 37094756
Solvent & Solubility
In Vitro:
DMSO : 16.67 mg/mL (43.26 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (4.33 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.67 mg/mL (4.33 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. McConville ML, et al. Effects of sarafloxacin hydrochloride on human enteric bacteria under simulated human gut conditions. Vet Q. 1995;17(1):1-5. [Content Brief]
[2]. Fernandes CJ, et al. In vitro activity of A-56619 and A-56620 against multi-resistant and routine clinical isolates. Chemotherapy. 1988;34(3):216-228. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5950 mL | 12.9749 mL | 25.9498 mL | 64.8744 mL |
| 5 mM | 0.5190 mL | 2.5950 mL | 5.1900 mL | 12.9749 mL | |
| 10 mM | 0.2595 mL | 1.2975 mL | 2.5950 mL | 6.4874 mL | |
| 15 mM | 0.1730 mL | 0.8650 mL | 1.7300 mL | 4.3250 mL | |
| 20 mM | 0.1297 mL | 0.6487 mL | 1.2975 mL | 3.2437 mL | |
| 25 mM | 0.1038 mL | 0.5190 mL | 1.0380 mL | 2.5950 mL | |
| 30 mM | 0.0865 mL | 0.4325 mL | 0.8650 mL | 2.1625 mL | |
| 40 mM | 0.0649 mL | 0.3244 mL | 0.6487 mL | 1.6219 mL |
Sarafloxacin Related Classifications
HY-B0343 Related Classifications
Powered by Bioz